Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Clinical manifestations and impact on daily life of allergy to polyethylene glycol (PEG) in ten patients

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Airway gene expression identifies subtypes of type 2 inflammation in severe asthma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Increased all-cause mortality in concomitant atopic dermatitis and asthma: A nationwide registry-based study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Treating severe asthma: targeting the IL-5 pathway

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  1. The transcriptome of hand eczema assessed by tape stripping

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Allergic contact dermatitis from dyes used in the temple of spectacles

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Does aluminium in sunscreens cause dermatitis in children with aluminium contact allergy: A repeated open application test study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Optimizing investigation of suspected allergy to polyethylene glycols

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

BACKGROUND: Polyethylene glycols (PEGs) are widely used as excipients in drugs, cosmetics and household products. Immediate-type allergy to PEGs including anaphylaxis is rare. The recent introduction of the mRNA-based COVID-19 vaccines has led to an increased focus on PEG as a possible culprit of allergic reactions to the vaccines. A low awareness of the allergenic potential of PEG among consumers, manufacturers and doctors leads to under-diagnosis and under-reporting of allergy to PEGs, putting patients at risk of repeated severe reactions.

OBJECTIVES: To investigate clinical manifestations, time to diagnosis and impact of a PEG allergy diagnosis on the daily life of patients diagnosed with allergy to PEG from 2010 to 2019.

METHOD: Ten patients diagnosed with allergy to PEG were included. Detailed clinical history was obtained, and allergy investigations had been performed at the time of diagnosis. All patients were contacted and asked to retrospectively complete a questionnaire about causes and impact on daily life of an allergy to PEG, scored on a likert scale (0-10) before and after diagnosis.

RESULTS: Eight patients had experienced at least one anaphylactic reaction requiring adrenaline treatment. Anaphylaxis was primarily caused by antibiotic/analgesic tablets, depot-steroids, antacids and laxatives. Seven patients reported repeated reactions before diagnosis (median 3, range 2-6). Median time from first reaction to diagnosis was 20 months (range 2-120). None of the patients experienced severe allergic reactions after the diagnosis. Median likert score of the impact on daily life before diagnosis was 7 compared with 4 after diagnosis.

CONCLUSION AND CLINICAL RELEVANCE: The clinical manifestations of PEG allergy are often dramatic. Improved awareness about the clinical presentation and common culprits, clear product labelling and a standardized nomenclature is needed to ensure the timely diagnosis of PEG allergy to prevent repeated anaphylactic reactions with severe impact on patients' lives.

OriginalsprogEngelsk
TidsskriftClinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
Vol/bind51
Udgave nummer3
Sider (fra-til)463-470
Antal sider8
ISSN0954-7894
DOI
StatusUdgivet - mar. 2021

ID: 64184296